Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  33.00 0.44% 7,592.00 7,566.00 7,568.00 7,588.00 7,503.00 7,533.00 4,411,246 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,386.4 1,167.2 77.7 100.9 99,600

FDA Grants Supplemental Approval to AstraZeneca's Calquence

21/11/2019 4:43pm

Dow Jones News

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Jan 2019 to Jan 2021

Click Here for more Astrazeneca Charts.

By Michael Dabaie


The U.S. Food and Drug Administration granted supplemental approval to AstraZeneca PLC (AZN) for Calquence to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

This new approved indication for Calquence provides a new treatment option for patients with CLL or SLL as an initial or subsequent therapy, the FDA said.

The FDA said the approval was part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada. Project Orbis provides a framework for concurrent submission and review of oncology drug applications among the FDA's international partners.

AstraZeneca ADRs were recently up 1% to $47.47.


Write to Michael Dabaie at


(END) Dow Jones Newswires

November 21, 2019 11:28 ET (16:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210115 18:58:06